Instil Bio Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Public

  • Employees
  • 17

Employees

  • Stock Symbol
  • TIL

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $5.55
  • (As of Thursday Closing)

Instil Bio General Information

Description

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 3963 Maple Avenue
  • Suite 350
  • Dallas, TX 75219
  • United States
+1 (972)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 3963 Maple Avenue
  • Suite 350
  • Dallas, TX 75219
  • United States
+1 (972)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Instil Bio Stock Performance

As of 19-Nov-2026, Instil Bio’s stock price is $5.55. Its current market cap is $37.6M with 6.78M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$5.55 $5.43 $5.14 - $13.50 $37.6M 6.78M 41.2K -$3.04

Instil Bio Financials Summary

As of 30-Sep-2026, Instil Bio has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 66,844 79,852 89,571 (47,628)
Revenue 0 0 0 0
EBITDA (17,248) (69,658) (69,515) (155,939)
Net Income (20,900) (71,372) (74,135) (156,087)
Total Assets 195,645 203,523 263,567 325,630
Total Debt 87,156 85,178 86,886 86,054
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Instil Bio Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Instil Bio‘s full profile, request access.

Request a free trial

Instil Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Instil Bio‘s full profile, request access.

Request a free trial

Instil Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous
Biotechnology
Dallas, TX
17 As of 2025

Santa Monica, CA
 

San Diego, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Instil Bio Competitors (7)

One of Instil Bio’s 7 competitors is Kite Pharma, a Formerly VC-backed company based in Santa Monica, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Kite Pharma Formerly VC-backed Santa Monica, CA
Poseida Therapeutics Formerly VC-backed San Diego, CA
Obsidian Therapeutics Formerly VC-backed Cambridge, MA
Iovance Biotherapeutics Corporation San Carlos, CA
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
You’re viewing 5 of 7 competitors. Get the full list »

Instil Bio Patents

Instil Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024263890-A2 Tumor-infiltrating lymphocyte (til) transduction methods Inactive 21-Jun-2023
WO-2024263890-A3 Tumor-infiltrating lymphocyte (til) transduction methods Inactive 21-Jun-2023
WO-2024243429-A2 Use of fusion constructs for cd4+ t cell therapy Inactive 24-May-2023
WO-2024243429-A3 Use of fusion constructs for cd4+ t cell therapy Inactive 24-May-2023
WO-2024243428-A2 Use of fusion constructs for cell therapy Inactive 24-May-2023 C07K14/7051
To view Instil Bio’s complete patent history, request access »

Instil Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Instil Bio Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Instil Bio‘s full profile, request access.

Request a free trial

Instil Bio Acquisitions (1)

Instil Bio’s most recent deal was a Merger/Acquisition with Immetacyte for . The deal was made on 02-Mar-2020.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Immetacyte 02-Mar-2020 Merger/Acquisition Drug Discovery
To view Instil Bio’s complete acquisitions history, request access »

Instil Bio ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

37.46 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Instil Bio’s complete esg history, request access »

Instil Bio FAQs

  • When was Instil Bio founded?

    Instil Bio was founded in 2018.

  • Where is Instil Bio headquartered?

    Instil Bio is headquartered in Dallas, TX.

  • What is the size of Instil Bio?

    Instil Bio has 17 total employees.

  • What industry is Instil Bio in?

    Instil Bio’s primary industry is Biotechnology.

  • Is Instil Bio a private or public company?

    Instil Bio is a Public company.

  • What is Instil Bio’s stock symbol?

    The ticker symbol for Instil Bio is TIL.

  • What is the current stock price of Instil Bio?

    As of 19-Nov-2026 the stock price of Instil Bio is $5.55.

  • What is the current market cap of Instil Bio?

    The current market capitalization of Instil Bio is $37.6M.

  • Who are Instil Bio’s competitors?

    Kite Pharma, Poseida Therapeutics, Obsidian Therapeutics, Iovance Biotherapeutics, and Adaptimmune Therapeutics are some of the 7 competitors of Instil Bio.

  • What is Instil Bio’s annual earnings per share (EPS)?

    Instil Bio’s EPS for 12 months was -$3.04.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process